Want to see JAGX full AI Analyst Report?
Top Page
Jaguar Animal Health
(NASDAQ:JAGX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$5.00
▲(481.40% Upside)
Action:Reiterated
Date:09/30/26
The score is weighed down primarily by weak financial quality—ongoing losses, thin equity, and a return to TTM cash burn—alongside a strong negative technical trend with the stock below all major moving averages. Corporate events provide some balance-sheet clean-up and strategic consolidation, but dilution and governance hurdles offset much of that benefit, and valuation support is limited given negative earnings and no dividend.
Positive Factors
High gross margin and revenue expansion
The company has expanded revenue materially over several years while retaining an approximately 82% TTM gross margin. This combination indicates meaningful commercial scale and product economics, creating a foundation for improved operating leverage if Jaguar can bring its cost structure closer to the current revenue base.
Negative Factors
Persistent operating losses
Sustained negative EBIT and net margins show that Jaguar has not yet converted its growing revenue base and strong gross margin into operating profitability. Until expenses become better aligned with sales, continued losses can consume capital, limit reinvestment capacity, and leave earnings dependent on future financing or revenue improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin and revenue expansion
The company has expanded revenue materially over several years while retaining an approximately 82% TTM gross margin. This combination indicates meaningful commercial scale and product economics, creating a foundation for improved operating leverage if Jaguar can bring its cost structure closer to the current revenue base.
Read all positive factors
Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.35M
Dividend YieldN/A
Average Volume (3M)2.49M
Price to Earnings (P/E)―
Beta (1Y)2.97
Revenue Growth135.52%
EPS Growth85.50%
CountryUS
Employees47
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5482.20
Shares Outstanding1,945,542
10 Day Avg. Volume7,413,445
30 Day Avg. Volume2,488,635
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.13
Price to Sales (P/S)0.19
P/FCF Ratio0.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-63
Revenue Forecast (FY)$2.46M
Jaguar Animal Health Business Overview & Revenue Model
Company Description
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are s...
How the Company Makes Money
Jaguar Animal Health primarily makes money through (1) product sales and (2) licensing/partnering related income when applicable.
1) Product sales (core revenue stream)
- Animal health product revenue: The company sells gastrointestinal products ...
Jaguar Animal Health Earnings Call Summary
Earnings Call Date:Apr 07, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Neutral
The call presented meaningful strategic and clinical positives — a sizable non-dilutive upfront/licensing arrangement, manufacturing revenue upside, and compelling proof-of-concept data with 12%–37% reductions in parenteral support and a targeted NDA timeline (H1 2027) for MVID. However, these positives are balanced by near-term commercial and financial challenges: YoY revenue decline, sustained and growing operating losses (net loss to $53.6M; Non-GAAP recurring EBITDA loss $48.1M), declining Mytesi prescription volumes, and increased dependency on partner milestone payments and manufacturing revenue under the out-license. Overall, the call communicated promising development and BD catalysts that could be transformative long term but also highlighted significant short-term financial pressures and commercialization trade-offs.Positive Updates
Non-Dilutive Licensing Deal with Future Pak
Closed U.S. out-license for Mytesi and Canalevia-CA1 with $18M upfront (company reported $16M received at signing, $2M conditional), additional ~$20M in potential milestone and future payments, and roughly $3M–$4M of additional payments already received. Jaguar will continue to manufacture crofelemer and recognize manufacturing revenue; the deal provides immediate non-dilutive cash to fund rare-disease development.
Negative Updates
Declining Mytesi Prescription Volume
Mytesi prescription volume declined ~3.7% in 2025 vs 2024, declined ~5.8% in Q4 2025 vs Q3 2025, and declined ~12.2% in Q4 2025 vs Q4 2024. Company notes specialty pharmacy inventory dynamics contribute to variability between prescription and invoiced sales volume.
Read all updates
Q4-2025 Updates
Positive
Negative
Non-Dilutive Licensing Deal with Future Pak
Closed U.S. out-license for Mytesi and Canalevia-CA1 with $18M upfront (company reported $16M received at signing, $2M conditional), additional ~$20M in potential milestone and future payments, and roughly $3M–$4M of additional payments already received. Jaguar will continue to manufacture crofelemer and recognize manufacturing revenue; the deal provides immediate non-dilutive cash to fund rare-disease development.
Read all positive updates
Company Guidance
The company’s guidance centers on “continued business development” in 2026 with near-term clinical, regulatory and BD catalysts over the next 6–12 months and a clear goal to license its crofelemer rare-disease program: target filing of an NDA for MVID in first half of 2027 (MVID global prevalence ≈200 patients) following completion of a fully enrolled placebo‑controlled trial (with ongoing treatment‑only extension), pursuit of FDA Breakthrough designation and EMA PRIME, and parallel Phase II randomized double‑blind placebo‑controlled development in short bowel syndrome‑IF (SBS‑IF; U.S. patient estimate ≈12,000) where third‑party market estimates put opportunity at ~$8 billion; proof‑of‑concept investigator data in three pediatric IF patients showed parenteral‑support reductions of 12%–37% (12.5%–15.6% in two SBS patients, ~37% in one MVID), with even 5% reductions described as meaningful; financial guidance emphasizes non‑dilutive funding (Future Pak licensing: $18M upfront with $16M received to date, $2M conditional, ~$20M in potential milestones and >$3M additional payments reported, Future Pak also paid $3M tied to termination of a buy‑back provision), Jaguar to remain manufacturer and recognize manufacturing revenue, Q4 2025 net revenue ≈$3.2M (+5% vs Q3 2025 $3.1M; −8% vs Q4 2024 $3.5M), 2025 total net revenue ≈$11.5M (≈$11.2M from Mytesi and Canalevia‑CA1), Mytesi prescription volume down ~3.7% in 2025 vs 2024 (Q4 2025 vs Q3 2025 down ~5.8%; Q4 2025 vs Q4 2024 down ~12.2%), loss from operations increased $15.1M to $45.9M in 2025, Non‑GAAP Recurring EBITDA net loss $48.1M (2025) vs $35.9M (2024), net loss attributable to common shareholders $53.6M (2025) vs $38.5M (2024), and the company expects these clinical, regulatory and BD milestones to drive partnership discussions and additional non‑dilutive funding.Jaguar Animal Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
27
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.82M | 11.51M | 11.69M | 9.76M | 11.96M | 4.33M |
| Gross Profit | 22.89M | 7.74M | 9.73M | 7.72M | 9.94M | 2.00M |
| EBITDA | -40.09M | -51.73M | -36.66M | -32.76M | -33.38M | -42.37M |
| Net Income | -36.65M | -53.43M | -38.49M | -41.30M | -47.45M | -52.59M |
Balance Sheet | ||||||
| Total Assets | 34.19M | 38.32M | 53.42M | 50.76M | 47.45M | 53.27M |
| Cash, Cash Equivalents and Short-Term Investments | 6.59M | 968.00K | 8.00M | 6.47M | 5.47M | 17.05M |
| Total Debt | 16.65M | 43.61M | 36.53M | 37.09M | 34.84M | 29.36M |
| Total Liabilities | 29.27M | 57.01M | 46.93M | 45.87M | 48.81M | 41.41M |
| Stockholders Equity | 6.62M | -17.29M | 7.29M | 4.96M | -657.00K | 11.61M |
Cash Flow | ||||||
| Free Cash Flow | -6.76M | 5.77M | -29.61M | -33.24M | -34.78M | -34.98M |
| Operating Cash Flow | -6.74M | 5.80M | -29.38M | -33.24M | -33.10M | -34.97M |
| Investing Cash Flow | -41.00K | 149.00K | -231.00K | 0.00 | -1.68M | -6.00K |
| Financing Cash Flow | 11.30M | -44.33M | 31.20M | 34.23M | 23.18M | 43.94M |
Jaguar Animal Health Technical Analysis
Negative
0.86
Price Trends
11.24
Negative
26.46
Negative
181.09
Negative
Market Momentum
-1.62
Negative
44.76
Neutral
7.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 0.86 is below the 20-day moving average (MA) of 7.26, below the 50-day MA of 11.24, and below the 200-day MA of 181.09, indicating a bearish trend. The MACD of -1.62 indicates Negative momentum. The RSI at 44.76 is Neutral, neither overbought nor oversold. The STOCH value of 7.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.
Jaguar Animal Health Risk Analysis
Jaguar Animal Health disclosed 70 risk factors in its most recent earnings report. Jaguar Animal Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jaguar Animal Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $7.97M | -0.04 | -210.99% | ― | -9.18% | 33.16% | |
41 Neutral | $10.35M | ― | 762.51% | ― | 135.52% | 85.50% | |
41 Neutral | $3.56M | -0.02 | -743.66% | ― | -100.00% | 77.63% | |
40 Underperform | $6.48M | -0.45 | 761.97% | ― | -80.59% | 59.44% |
* Healthcare Sector Average
JAGX
Jaguar Animal Health
4.50
-1,166.25
-99.62%
EVGN
Evogene
0.40
-0.75
-65.48%
GOVX
GeoVax Labs
0.33
-13.14
-97.52%
CODX
Co-Diagnostics
1.07
-9.52
-89.90%
Jaguar Animal Health Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Jaguar Animal Health Executes Major Debt-for-Equity Exchange
Neutral
Sep 25, 2026
On September 23, 2026, Jaguar Health entered privately negotiated exchange agreements with Streeterville Capital under which it issued 182,091 common shares to reduce by $1,678,320 the outstanding balance of a secured promissory note originally is...
Business Operations and StrategyPrivate Placements and Financing
Jaguar Animal Health Reduces Debt Through Equity Exchange
Neutral
Sep 24, 2026
On November 12, 2025, Jaguar Health, Inc. issued a secured promissory note with an original principal amount of $10.81 million to Streeterville Capital, LLC under a note purchase agreement between the parties. The note formed part of the company&#...
Business Operations and StrategyRegulatory Filings and ComplianceStock Split
Jaguar Animal Health Announces Major Equity Recapitalization
Neutral
Sep 21, 2026
On September 15, 2026, Jaguar Health filed a Certificate of Elimination in Delaware to remove multiple previously designated preferred stock series from its charter, returning those shares to authorized but undesignated preferred stock after all s...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Jaguar Animal Health expands ownership and restructures equity
Negative
Sep 15, 2026
On September 11, 2026, Jaguar Health exchanged a 6% convertible promissory note held by Lincoln Alternative Strategies for 557,377 shares of common stock, cancelling the $175,016.36 note balance and further shifting its liabilities into equity. Be...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Jaguar Animal Health Announces Reverse Stock Split Plans
Neutral
Sep 15, 2026
Jaguar Health, Inc. is a biopharmaceutical company that develops novel proprietary prescription drugs sustainably derived from plants for patients with complicated gastrointestinal disease states. Through its subsidiaries Napo Pharmaceuticals and ...
Business Operations and StrategyShareholder Meetings
Jaguar Health Faces Shareholder Quorum Challenge at Meeting
Negative
Sep 4, 2026
On September 4, 2026, Jaguar Health convened a special meeting of stockholders but failed to secure a quorum of voting common and Series Q preferred shares, preventing any votes or business from being conducted. The company stated it will not reco...
Business Operations and Strategy
Jaguar Animal Health Signs New Crofelemer Supply Agreement
Positive
Jul 15, 2026
On July 9, 2026, Napo Pharmaceuticals entered a new manufacturing and supply agreement with Alivus Life Sciences to continue producing crofelemer for Mytesi® and other crofelemer‑based products. The deal replaces a prior agreement that ...
Business Operations and StrategyDividendsStock Split
Jaguar Health Completes Conversion of Series O Preferred
Positive
Jul 1, 2026
On March 4, 2026, Jaguar Health paid a special one-time dividend of Series O Convertible Preferred Stock tied to its outstanding voting common shares and certain dividend-rights warrants, based on a March 2, 2026 record date and retroactively adju...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.